N J White1, E Mehic2, X Wang1, D Chien1, E Lim1, A E St John1, S A Stern1, P D Mourad2,3, M Rieger4, D Fries5, U Martinowitz6. 1. Division of Emergency Medicine, University of Washington, Seattle, WA, USA. 2. Department of Neurological Surgery, University of Washington, Seattle, WA, USA. 3. Division of Engineering and Mathematics, University of Washington, Bothell, WA, USA. 4. Department of Diagnostic & Interventional Radiology, Medical Clinic Innsbruck, Innsbruck, Austria. 5. Clinical Department for General and Surgical Intensive Care Medicine of the Clinic for Anaesthesia and General Intensive Care Medicine, Medical Clinic Innsbruck, Innsbruck, Austria. 6. Department for Hematology, TelHashomer University Hospital, Telaviv, Israel.
Abstract
BACKGROUND: Treatments for major internal bleeding after injury include permissive hypotension to decrease the rate of blood loss, intravenous infusion of plasma or clotting factors to improve clot formation, and rapid surgical hemostasis or arterial embolization to control bleeding vessels. Yet, little is known regarding major internal arterial hemostasis, or how these commonly used treatments might influence hemostasis. OBJECTIVES: (i) To use a swine model of femoral artery bleeding to understand the perivascular hemostatic response to contained arterial hemorrhage. (ii) To directly confirm the association between hemodynamics and bleeding velocity. (iii) To observe the feasibility of delivering an activated clotting factor directly to internal sites of bleeding using a simplified angiographic approach. METHODS: Ultrasound was used to measure bleeding velocity and in vivo clot formation by elastography in a swine model of contained femoral artery bleeding with fluid resuscitation. A swine model of internal pelvic and axillary artery hemorrhage was also used to demonstrate the feasibility of local delivery of an activated clotting factor. RESULTS: In this model, clots formed slowly within the peri-wound hematoma, but eventually contained the bleeding. Central hemodynamics correlated positively with bleeding velocity. Infusion of recombinant human activated factor VII into the injured artery near the site of major internal hemorrhage in the pelvis and axillae was feasible. CONCLUSIONS: We rediscovered that clot formation within the peri-wound hematoma is an integral component of hemostasis and a feasible target for the treatment of major internal bleeding using activated clotting factors delivered using a simplified angiographic approach.
BACKGROUND: Treatments for major internal bleeding after injury include permissive hypotension to decrease the rate of blood loss, intravenous infusion of plasma or clotting factors to improve clot formation, and rapid surgical hemostasis or arterial embolization to control bleeding vessels. Yet, little is known regarding major internal arterial hemostasis, or how these commonly used treatments might influence hemostasis. OBJECTIVES: (i) To use a swine model of femoral artery bleeding to understand the perivascular hemostatic response to contained arterial hemorrhage. (ii) To directly confirm the association between hemodynamics and bleeding velocity. (iii) To observe the feasibility of delivering an activated clotting factor directly to internal sites of bleeding using a simplified angiographic approach. METHODS: Ultrasound was used to measure bleeding velocity and in vivo clot formation by elastography in a swine model of contained femoral artery bleeding with fluid resuscitation. A swine model of internal pelvic and axillary artery hemorrhage was also used to demonstrate the feasibility of local delivery of an activated clotting factor. RESULTS: In this model, clots formed slowly within the peri-wound hematoma, but eventually contained the bleeding. Central hemodynamics correlated positively with bleeding velocity. Infusion of recombinant human activated factor VII into the injured artery near the site of major internal hemorrhage in the pelvis and axillae was feasible. CONCLUSIONS: We rediscovered that clot formation within the peri-wound hematoma is an integral component of hemostasis and a feasible target for the treatment of major internal bleeding using activated clotting factors delivered using a simplified angiographic approach.
Authors: E Hornez; O Maurin; S Bourgouin; J Cotte; T Monchal; J de Roulhac; L Meyrat; J-P Platel; G Delort; E Meaudre; H Thouard Journal: J Visc Surg Date: 2011-10-22 Impact factor: 2.043
Authors: Jonathan Bain; Daniel Lewis; Andrew Bernard; Kevin Hatton; Hassan Reda; Jeremy Flynn Journal: J Thromb Thrombolysis Date: 2014-11 Impact factor: 2.300
Authors: Carl J Hauser; Kenneth Boffard; Richard Dutton; Gordon R Bernard; Martin A Croce; John B Holcomb; Ari Leppaniemi; Michael Parr; Jean-Louis Vincent; Bartholomew J Tortella; Jeannett Dimsits; Bertil Bouillon Journal: J Trauma Date: 2010-09
Authors: Bijan S Kheirabadi; Françoise Arnaud; Richard McCarron; Alan D Murdock; Douglas L Hodge; Brandi Ritter; Michael A Dubick; Lorne H Blackbourne Journal: J Trauma Date: 2011-07
Authors: Juan C Duchesne; James M Barbeau; Tareq M Islam; Georgia Wahl; Patrick Greiffenstein; Norman E McSwain Journal: Am Surg Date: 2011-02 Impact factor: 0.688
Authors: Zinnia S Xu; Rona J Lee; Stephanie S Chu; Anning Yao; Marla K Paun; Sean P Murphy; Pierre D Mourad Journal: J Ultrasound Med Date: 2013-03 Impact factor: 2.153
Authors: Patrick M Osborn; Wade R Smith; Ernest E Moore; C Clay Cothren; Steven J Morgan; Allison E Williams; Philip F Stahel Journal: Injury Date: 2008-11-30 Impact factor: 2.586
Authors: Sharmila Jasmine; Annamalai Thangavelu; Rajapandiyan Krishnamoorthy; Mohammed A Alshuniaber; Ali A Alshatwi Journal: Oral Maxillofac Surg Date: 2020-09-11